SICHUAN, China, October 11, 2012 /PRNewswire/ -- China Health Resource, Inc. (OTCBB: CHRI) announced today it has extended its strategic agreement with the prestigious Chengdu University of Traditional Chinese Medicine.
"Our ability to provide pharmaceutical grade herbs and proprietary products from our certified GAP ingredients allows us to earn higher profit margins and protect our franchise. This cooperation with the prestigious Chengdu University of TCM in addition to our internal R&D provides us with this ability" says Jiayin Wang, Chairman and CEO of the Company.
The Chengdu University of Traditional Chinese Medicine (TCM) is one of the oldest and most established TCM educational and research institutions in China and a long term research partner of the Company's subsidiary Yin Fa. Yinfa and the University initial "Comprehensive Strategic Cooperation Agreement," started Feb 12, 2006 and its scientific assistance resulted in the establishment of the GAP standard for Dahurian Angelica Root (DAR). This cooperation agreement extended in 2010 for research efforts for the pharmaceutical usage and enhancement of DAR which in 2011 extended the agreement for Gastroria ("Tianma").
"CHRI is leveraging its success in creating the fist and only pharmaceutical grade GAP standard Dahurian Angelica Root (DAR) product in the market, extending it to Gastroria - a higher profit margin product, and we are now in a position to develop a medical products using herbal medicines that can compete in the international market place while continuing to protect our DAR franchise in China" added Jiayin Wang.
Gastroria is one of the more expensive TCM products in today's market and is used to treat headaches, dizziness, numbness, convulsions in children, and epilepsy. "Our R&D efforts with the most advanced research capabilities of the Chengdu University will lead to the best quality and products and further enhance CHRI role in TCM. In addition, the certification awarded by the government as a sanctioned quality enterprise and our partnership with the leading and longest standing TCM research institution gives us a unique strategic position to discover valuable healthcare products for the community" said Jiayin Wang, Chairman and CEO of CHRI.
Press Contact:
info@chinahealthresource.com
www.chinahealthresource.com
About CHRI
China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is only the provider of GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi™. DAR, which is also known as "Bai Zhi" in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The Company's DAR-related products include the Bailing Capsule and Yishen Capsule, all of which are sold through regional distributors. The Company was founded in 2001.
Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.
Contact Information:
Ms. Cynthia Bitting
Tel: +1 314-442-0368 (USA)
